FARINATI, FABIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.368
EU - Europa 3.403
AS - Asia 3.012
SA - Sud America 25
AF - Africa 23
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 12
Totale 35.860
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 29.315
CN - Cina 1.682
SG - Singapore 1.004
IT - Italia 849
FI - Finlandia 627
DE - Germania 474
SE - Svezia 430
FR - Francia 311
UA - Ucraina 256
GB - Regno Unito 255
VN - Vietnam 146
IE - Irlanda 68
HK - Hong Kong 59
IN - India 42
CA - Canada 26
NL - Olanda 22
BR - Brasile 19
BG - Bulgaria 16
JP - Giappone 14
MX - Messico 14
GR - Grecia 13
AU - Australia 12
RU - Federazione Russa 12
TR - Turchia 12
BZ - Belize 11
EU - Europa 10
RO - Romania 10
TW - Taiwan 10
AT - Austria 8
HR - Croazia 8
EG - Egitto 7
IR - Iran 6
SC - Seychelles 6
ES - Italia 5
NZ - Nuova Zelanda 5
BE - Belgio 4
DK - Danimarca 4
ID - Indonesia 4
IL - Israele 4
PK - Pakistan 4
PL - Polonia 4
PT - Portogallo 4
SA - Arabia Saudita 4
AR - Argentina 3
NO - Norvegia 3
PH - Filippine 3
RS - Serbia 3
TH - Thailandia 3
TN - Tunisia 3
UG - Uganda 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
ET - Etiopia 2
HU - Ungheria 2
KR - Corea 2
KZ - Kazakistan 2
MD - Moldavia 2
MK - Macedonia 2
MN - Mongolia 2
MT - Malta 2
MY - Malesia 2
NP - Nepal 2
SK - Slovacchia (Repubblica Slovacca) 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
CH - Svizzera 1
CL - Cile 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
GE - Georgia 1
IQ - Iraq 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
ME - Montenegro 1
PA - Panama 1
PE - Perù 1
PR - Porto Rico 1
SI - Slovenia 1
ZA - Sudafrica 1
Totale 35.860
Salva come PNG Salva come JPEG
Città #
Fairfield 5.085
Woodbridge 3.462
Houston 2.889
Ann Arbor 2.189
Ashburn 1.948
Chandler 1.920
Seattle 1.735
Wilmington 1.709
Cambridge 1.651
Jacksonville 1.278
Singapore 738
Princeton 692
San Diego 608
Roxbury 371
Medford 341
Beijing 322
Guangzhou 275
Nanjing 267
Padova 243
Des Moines 242
Helsinki 232
Boardman 170
Dong Ket 140
Santa Clara 131
Shanghai 124
New York 117
Norwalk 91
Shenyang 78
Hebei 74
Nanchang 74
London 69
Dublin 63
Falls Church 59
Jiaxing 54
Changsha 49
Tianjin 44
Milan 36
Redwood City 34
Chicago 32
Ogden 32
Rome 32
Jinan 27
Kharkiv 27
Washington 25
Los Angeles 24
San Jose 24
Kilburn 22
Indiana 21
Chiswick 20
Borås 18
Las Vegas 18
Bologna 17
Sofia 16
Detroit 15
Tappahannock 15
Turin 13
Zhengzhou 13
Dearborn 12
Hefei 12
Hounslow 12
Belize City 11
Hangzhou 11
Hong Kong 11
Columbus 10
Lappeenranta 10
Pune 10
Tokyo 10
Dallas 9
Florence 9
Paris 9
Phoenix 9
Prescot 9
San Francisco 9
Verona 9
Frankfurt am Main 8
Nürnberg 8
Santa Maria di Sala 8
Taipei 8
Taizhou 8
Zagreb 8
Arezzo 7
Buffalo 7
Edinburgh 7
Kunming 7
Legnaro 7
Mexico City 7
Ningbo 7
Palermo 7
Pisa 7
Rockville 7
Venice 7
Haikou 6
Modena 6
Munich 6
Naples 6
New Bedfont 6
Orange 6
Southwark 6
São Paulo 6
Toronto 6
Totale 30.366
Salva come PNG Salva come JPEG
Nome #
Effects of N-acetyl-L-cysteine in patients with chronic atrophic gastritis and nonulcer dyspepsia: A phase III pilot study 239
Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study 195
Changes in microRNA expression during disease progression in patients with chronic viral hepatitis 157
Circulating free DNA in the progression of liver damage to hepatocellular carcinoma 155
Treatment of hepatocellular carcinoma in the Precision Medicine era: from treatment stage migration to therapeutic hierarchy 154
Autoimmune gastritis: histology phenotype and OLGA staging. 153
Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases 150
Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. 146
The Veneto Region's Barrett's Oesophagus Registry: Aims, methods, preliminary results. 143
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 143
Partial hepatectomy as first-line treatment for patients with hepatocellular carcinoma 141
Molecular characterization of “sessile serrated” adenoma to carcinoma transition in six early colorectal cancers 141
Prospective validation of the Barcelona Clinic Liver Cancer staging system 141
Development of retroviral vectors for combined suicide and immunomodulating gene therapy of hepatocellular carcinoma (HCC) 138
BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling 137
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice 135
Hepatitis C virus eradication with direct acting antiviral improves insulin resistance 135
Capecitabine in advanced hepatocellular carcinoma: A multicenter experience 134
Surveillance for hepatocellular carcinoma in cirrhosis: is it cost-effective? 132
The survival benefit of liver transplantation in hepatocellular carcinoma patients 129
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma 129
Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment 128
Gastroenterological oncology: a top priority 126
Squamous cell carcinoma antigen in human liver carcinogenesis. 126
Oxidative damage in the progression of chronic liver disease to hepatocellular carcinoma: An intricate pathway. 125
Barrett's epithelium after antireflux surgery 123
Autoimmune gastritis: Pathologist's viewpoint 123
Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the milan criteria 122
Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus-related liver carcinogenesis 122
Laparoscopic Ablation of Hepatocellular Carcinoma in Cirrhotic Patients Unsuitable for Liver Resection or Percutaneous Treatment: A Cohort Study 121
Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers. 120
Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. 120
Percutaneous radiofrequency thermal ablation for hepatocellular carcinoma. 119
Zinc, iron, and peroxidation in liver tissue. Cumulative effects of alcohol consumption and virus-mediated damage--a preliminary report. 118
Gastric type I carcinoid: a pilot study with human G17DT immunogen vaccination. 118
Alphafetoprotein and Transplant Survival Benefit For Patients With Hepatocellular Carcinoma: A Multicentre Cohort Study 118
Atrophic gastritis: pathology and endoscopy in the reversibility assessment. 118
Drop-out rate from the liver transplant waiting list due to HCC progression in HCV-infected patients treated with direct acting antivirals. 118
Retroviral-mediated combined suicide and immunomodulating gene therapy of hepatocellular carcinoma (HCC): An in vitro and in vivo study 118
Tryptophan hydroxylase autoantibodies as markers of a distinct autoimmune gastrointestinal component of autoimmune polyendocrine syndrome type 1. 118
Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis 117
A reappraisal of the Barcelona Clinic Liver Cancer model: natural history of untreated 'intermediate stage' hepatocellular carcinoma. 116
The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study 116
The evolutionary scenario of hepatocellular carcinoma in Italy: an update 115
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. 114
Experimental hepatology applied to stem cells 114
Oxidative DNA Damage in Barrett Mucosa: Correlation with Telomeric Dysfunction and p53 Mutation. 113
Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies. 113
Programmed cell death-ligand 1 (PD-L1) overexpression in ampulla of Vater carcinoma and its pre-invasive lesions 113
Let-7c down-regulation in Helicobacter pylori-related gastric carcinogenesis 113
Alcohol metabolism in the upper digestive tract: its implications with respect to carcinogenesis. 113
miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis 112
Oxidative DNA damage in circulating leukocytes occurs as an early event in chronic HCV infection. 111
"DAA in patients with Hepatocellular carcinoma before Liver Transplantation: are we sure is still an open issue?" 111
Re: Helicobacter pylori and atrophic gastritis: Importance of the cagA status. 110
Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma 110
Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. 109
Autophagy and apoptosis-related genes in chronic liver disease and hepatocellular carcinoma. 109
OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients 109
Videolaparoscopic microwave ablation in patients with HCC at a European high-volume center: Results of 815 procedures 109
Does the choice of treatment influence survival of patients with small hepatocellular carcinoma in compensated cirrhosis? 108
Oxidative Stress and Inducible Nitric Oxide Synthase Induction in Carcinogenesis 108
Squamous Cellular Carcinoma Antigen Serum Determination as a Biomarker of Barrett Esophagus and Esophageal Cancer: A Phase III Study 107
Proteases in gastrointestinal neoplastic diseases 107
The role of Cysteine and Serine Proteases in Colorectal Carcinoma 106
Sorafenib use in the transplant setting. 106
A phase I-II study of liposomal doxorubicin (LD) in the treatment of hepatocellular carcinoma (HCC) not suitable for loco-regional therapy. 105
Expression of squamous cell carcinoma antigen in hepatocellular carcinoma and its precursors 105
Up and down regulation of apoptosis in hepatitis C virus-related liver damage 105
Molecular targeted therapy in hepatocellular carcinoma: present achievements and future challenges. 105
Advanced precancerous lesions in the liver. 105
Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor 104
Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma 104
Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma 104
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. 103
Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotype 103
Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness 103
LAPAROSCOPIC ABLATION AND SALVAGE TRANSPLANTATION FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA 103
Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study. 103
Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma 103
Is mild gastric epithelial dysplasia an indication for follow-up? 103
Abnormal liver function tests in COVID-19 patients: relevance and potential pathogenesis 103
GASTRIC EPITHELIAL DYSPLASIA IN THE NATURAL-HISTORY OF GASTRIC- CANCER - A MULTICENTER PROSPECTIVE FOLLOW-UP-STUDY 102
THE SURVIVAL BENEFIT OF LIVER TRANSPLANTATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA 102
The changing scenario of hepatocellular carcinoma over the last two decades in Italy. 102
Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature. 102
Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres. 102
Diagnostic and Prognostic Role of Scca-IgM Serum Levels in Hepatocellular Carcinoma (Hcc). 102
Urokinase-type plasminogen activator in gastric cancer: tissue expression and prognostic role 101
Direct involvement of human gastric mucosa in the activation of alimentary pro-carcinogens. 101
The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. 101
Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria 101
An oncolytic adenovirus controlled by a modified telomerase promoter is attenuated in telomerase-negative cells, but shows reduced activity in cancer cells. 100
Early miR-223 Upregulation in Gastroesophageal Carcinogenesis 100
Combined suicide/cytokine gene therapy of hepatocellular carcinoma 99
Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma 99
Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. 99
Coffee, chronic diseases and cancer. 99
GASTRIC EPITHELIAL DYSPLASIA - A PROSPECTIVE MULTICENTER FOLLOW-UP-STUDY FROM THE INTERDISCIPLINARY-GROUP-ON-GASTRIC- EPITHELIAL-DYSPLASIA 98
Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study 98
Totale 11.786
Salva come PNG Salva come JPEG
Categoria #
all - tutte 135.143
article - articoli 130.362
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 625
Totale 266.130
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.589 0 0 0 634 808 543 660 795 752 645 396 356
2020/20214.821 216 380 295 418 155 315 237 552 717 450 550 536
2021/20227.062 174 769 952 514 241 411 661 712 279 161 771 1.417
2022/20234.397 936 359 81 511 727 599 55 320 506 35 227 41
2023/20242.645 143 316 272 173 157 299 155 72 190 316 273 279
2024/20251.391 42 590 482 277 0 0 0 0 0 0 0 0
Totale 36.223